The trial that changed what these drugs are for

What this comes down to

• SELECT enrolled 17,604 patients aged 45 or older with preexisting cardiovascular disease, a body-mass index of 27 or greater and no history of diabetes, and followed them for a mean of 39.8 months.
• A primary endpoint event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group: a hazard ratio of 0.80, with the trial's stated P value below 0.001.
• Adverse events leading to permanent discontinuation occurred in 16.6% of the semaglutide group against 8.2% on placebo. One in six people stopped.
• The approved semaglutide label now leads with the cardiovascular indication. That is an indication a payer's weight-loss exclusion does not automatically cover.

What SELECT did

It was a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial. Patients aged 45 or older with preexisting cardiovascular disease, a body-mass index of 27 or greater and no history of diabetes were assigned one-to-one to once-weekly subcutaneous semaglutide at 2.4 mg or placebo. The primary endpoint was a composite of death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke, in a time-to-first-event analysis^[1]. Note the design words: double-blind, placebo-controlled, event-driven. This is a different quality of evidence from an open-label weight comparison, and it should be read that way.

A primary endpoint event occurred in 569 of 8,803 patients on semaglutide, 6.5%, and in 701 of 8,801 on placebo, 8.0%, giving a hazard ratio of 0.80 with a 95% confidence interval of 0.72 to 0.90. Mean exposure was 34.2 months and mean follow-up 39.8 months^[1].

What it put on the label

The approved semaglutide weight product now carries, as its first listed indication, reduction of the risk of major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight^[2]. The approved oral semaglutide tablet carries a version of it as well^[3]. The approved tirzepatide weight product does not carry a cardiovascular indication at all: its two indications are weight and obstructive sleep apnea^[4].

That asymmetry is the practical content of this page. Two molecules that a telehealth site will sell you at adjacent prices have different approved indications, and an approved indication is the unit a payer's exclusion is written against. The federal exclusion and what it reaches covers the mechanics; the state map covers who has used it. The oral tablet carries a version of the same indication in the diabetes population^[3], and how much of the surrounding literature is independent rather than a secondary analysis is its own question^[5].

semaglutide[tiab] AND ("cardiovascular outcomes"[tiab] OR "major adverse cardiovascular"[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]

What it means when you are buying

• The cardiovascular result is the strongest evidence in this whole category, and it applies to a specific population: established cardiovascular disease, overweight or obesity, no diabetes. It is not a general claim about hearts.
• The indication belongs to one molecule. A site that sells you the other one has sold you a product without it, whatever the landing page implies.
• Compounded versions carry no indication at all, because they are not approved products. What the compounded and brand categories actually are sets out why that follows.
• Sixteen point six percent stopped for adverse events in a closely supervised trial. Price a twelve-month prepaid plan against that number, not against the brochure — refund and cancellation terms is what decides how much of it you get back.

Questions people actually ask